In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass discuss the continuing backlash from pharmacy benefits manager Express Scripts (NASDAQ:ESRX) against the price point Gilead (NASDAQ:GILD) has set for its blockbuster hepatitis C drug Sovaldi.
They discuss Express Scripts' position that price points like Sovaldi's aren't sustainable for customers, and they also look at the company's hints at strategic initiatives it may take if Gilead doesn't relent on Sovaldi's cost. The guys also discuss the bad news from Express Scripts' earnings report, and why the market's resulting sell-off may have been an overreaction.
Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.
David Williamson owns shares of Express Scripts. The Motley Fool recommends and owns shares of Express Scripts and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.